• Search
  • Helpdesk
  • Sales contact

Kayentis signs up 5 new phase III clinical studies

18 November 2015

These phase III clinical studies, supported by Top10 pharma laboratories, will be using the tablet-based data capture solution developed by Kayentis. They will be conducted in 700 research centers in 50 countries and will affect 5,000 patients.

Signing up these clinical studies has confirmed the presence of Kayentis as a global player in the capture and management of patient data (eClinical Outcome Assessment). For Guillaume Juge, « the success achieved among these leading laboratories has confirmed our ambition to offer the pharmaceutical industry high-level, dependable solutions for performant economic conditions ».

As experts in electronic data capture for patients in clinical trials, Kayentis has been involved in clinical development since 2003, helping sponsors and CROs to bring simplicity to the collection of clinical trials data for both patients and sites. Since 2009, Kayentis has specialized in eCOA solutions, developing a full range of services and extending its solutions portfolio. The company has continued to enhance its services and now offers a wide range of solutions that are easily used together and adaptable for all clinical study needs.

Follow us on social media
Subscribe to our newsletter
About the author
Meet us at the following events

Mobile in Clinical Trials

16 SEPT 2024 • Philadelphia, USA

DPharm 2024

17-18 SEPT 2024 • Philadelphia, USA

SCDM 2024

29 SEPT - 2 OCT 2024 • Boston, USA


13-16 OCT 2024 • Cologne, Germany


10-13 NOV 2024 • Cologne, Germany

DMB 2024

13 NOV 2024 • Paris, France

SCOPE 2025

FEB 3-6 2025 • Orlando, USA
Booth #931 https://www.scopesummit.com/